APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Psoriasis Biosimilar

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Psoriasis Biosimilar Market Analysis and Forecast 2026-2032

Report ID 174029790227 December 2025199 pages

Choose your research edition.

Industry ResearchPsoriasis Biosimilar Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Psoriasis Biosimilar Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Psoriasis Biosimilar Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Psoriasis Biosimilar Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Psoriasis Biosimilar Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Psoriasis Biosimilar market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Psoriasis Biosimilar is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Psoriasis Biosimilar is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Psoriasis Biosimilar is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Psoriasis Biosimilar is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Psoriasis Biosimilar include Amgen Inc, Celltrion, Coherus BioSciences, Fresenius Kabi, GenScript, Gyros Protein Technologies AB, Hoffmann-La Roche Ltd, Novartis International AG and Reddy's Laboratories, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Psoriasis Biosimilar, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Psoriasis Biosimilar, also provides the revenue of main regions and countries. Of the upcoming market potential for Psoriasis Biosimilar, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Psoriasis Biosimilar revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Psoriasis Biosimilar market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Psoriasis Biosimilar revenue, projected growth trends, production technology, application and end-user industry.

Psoriasis Biosimilar Segment by Company

Amgen Inc

Celltrion

Coherus BioSciences

Fresenius Kabi

GenScript

Gyros Protein Technologies AB

Hoffmann-La Roche Ltd

Novartis International AG

Reddy's Laboratories

Samsung Bioepis

Samsung Bioepis Co., Ltd.

Viatris

Pfizer Inc.

Merck KGaA

Sandoz

Psoriasis Biosimilar Segment by Type

TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)

Other Biosimilars

Psoriasis Biosimilar Segment by Application

Plaque Psoriasis

Psoriatic Arthritis

Other

Psoriasis Biosimilar Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psoriasis Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Psoriasis Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psoriasis Biosimilar.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Psoriasis Biosimilar in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Psoriasis Biosimilar company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Psoriasis Biosimilar revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Psoriasis Biosimilar Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab) Major Player Table 3. Other Biosimilars Major Player Table 4. Global Psoriasis Biosimilar Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Plaque Psoriasis Major Player Table 6. Psoriatic Arthritis Major Player Table 7. Other Major Player Table 8. Psoriasis Biosimilar Industry Trends Table 9. Psoriasis Biosimilar Industry Drivers Table 10. Psoriasis Biosimilar Industry Opportunities and Challenges Table 11. Psoriasis Biosimilar Industry Restraints Table 12. Global Psoriasis Biosimilar Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Psoriasis Biosimilar Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Psoriasis Biosimilar Market Share by Region (2021-2026) Table 15. Global Psoriasis Biosimilar Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Psoriasis Biosimilar Market Share by Region (2027-2032) Table 17. Global Psoriasis Biosimilar Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Psoriasis Biosimilar Revenue Market Share by Players (2021-2026) Table 19. Global Psoriasis Biosimilar Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Psoriasis Biosimilar Key Players Headquarters & Area Served Table 21. Global Psoriasis Biosimilar Players, Product Type & Application Table 22. Global Psoriasis Biosimilar Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Psoriasis Biosimilar by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Psoriasis Biosimilar Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Psoriasis Biosimilar Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Psoriasis Biosimilar Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Psoriasis Biosimilar Revenue Market Share by Type (2021-2026) Table 29. Global Psoriasis Biosimilar Revenue Market Share by Type (2027-2032) Table 30. Global Psoriasis Biosimilar Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Psoriasis Biosimilar Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Psoriasis Biosimilar Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Psoriasis Biosimilar Revenue Market Share by Application (2021-2026) Table 34. Global Psoriasis Biosimilar Revenue Market Share by Application (2027-2032) Table 35. Amgen Inc Company Information Table 36. Amgen Inc Business Overview Table 37. Amgen Inc Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Amgen Inc Psoriasis Biosimilar Product Portfolio Table 39. Amgen Inc Recent Development Table 40. Celltrion Company Information Table 41. Celltrion Business Overview Table 42. Celltrion Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Celltrion Psoriasis Biosimilar Product Portfolio Table 44. Celltrion Recent Development Table 45. Coherus BioSciences Company Information Table 46. Coherus BioSciences Business Overview Table 47. Coherus BioSciences Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Coherus BioSciences Psoriasis Biosimilar Product Portfolio Table 49. Coherus BioSciences Recent Development Table 50. Fresenius Kabi Company Information Table 51. Fresenius Kabi Business Overview Table 52. Fresenius Kabi Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Fresenius Kabi Psoriasis Biosimilar Product Portfolio Table 54. Fresenius Kabi Recent Development Table 55. GenScript Company Information Table 56. GenScript Business Overview Table 57. GenScript Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. GenScript Psoriasis Biosimilar Product Portfolio Table 59. GenScript Recent Development Table 60. Gyros Protein Technologies AB Company Information Table 61. Gyros Protein Technologies AB Business Overview Table 62. Gyros Protein Technologies AB Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Gyros Protein Technologies AB Psoriasis Biosimilar Product Portfolio Table 64. Gyros Protein Technologies AB Recent Development Table 65. Hoffmann-La Roche Ltd Company Information Table 66. Hoffmann-La Roche Ltd Business Overview Table 67. Hoffmann-La Roche Ltd Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Hoffmann-La Roche Ltd Psoriasis Biosimilar Product Portfolio Table 69. Hoffmann-La Roche Ltd Recent Development Table 70. Novartis International AG Company Information Table 71. Novartis International AG Business Overview Table 72. Novartis International AG Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Novartis International AG Psoriasis Biosimilar Product Portfolio Table 74. Novartis International AG Recent Development Table 75. Reddy's Laboratories Company Information Table 76. Reddy's Laboratories Business Overview Table 77. Reddy's Laboratories Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Reddy's Laboratories Psoriasis Biosimilar Product Portfolio Table 79. Reddy's Laboratories Recent Development Table 80. Samsung Bioepis Company Information Table 81. Samsung Bioepis Business Overview Table 82. Samsung Bioepis Psoriasis Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Samsung Bioepis Psoriasis Biosimilar Product Portfolio Table 84. Samsung Bioepis Recent Development Table 85. Samsung Bioepis Co., Ltd. Company Information Table 86. Samsung Bioepis Co., Ltd. Business Overview Table 87. Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Product Portfolio Table 89. Samsung Bioepis Co., Ltd. Recent Development Table 90. Viatris Company Information Table 91. Viatris Business Overview Table 92. Viatris Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Viatris Psoriasis Biosimilar Product Portfolio Table 94. Viatris Recent Development Table 95. Pfizer Inc. Company Information Table 96. Pfizer Inc. Business Overview Table 97. Pfizer Inc. Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Pfizer Inc. Psoriasis Biosimilar Product Portfolio Table 99. Pfizer Inc. Recent Development Table 100. Merck KGaA Company Information Table 101. Merck KGaA Business Overview Table 102. Merck KGaA Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Merck KGaA Psoriasis Biosimilar Product Portfolio Table 104. Merck KGaA Recent Development Table 105. Sandoz Company Information Table 106. Sandoz Business Overview Table 107. Sandoz Psoriasis Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Sandoz Psoriasis Biosimilar Product Portfolio Table 109. Sandoz Recent Development Table 110. North America Psoriasis Biosimilar Revenue by Type (2021-2026) & (US$ Million) Table 111. North America Psoriasis Biosimilar Revenue by Type (2027-2032) & (US$ Million) Table 112. North America Psoriasis Biosimilar Revenue by Application (2021-2026) & (US$ Million) Table 113. North America Psoriasis Biosimilar Revenue by Application (2027-2032) & (US$ Million) Table 114. North America Psoriasis Biosimilar Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. North America Psoriasis Biosimilar Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Psoriasis Biosimilar Revenue by Country (US$ Million) & (2027-2032) Table 117. Europe Psoriasis Biosimilar Revenue by Type (2021-2026) & (US$ Million) Table 118. Europe Psoriasis Biosimilar Revenue by Type (2027-2032) & (US$ Million) Table 119. Europe Psoriasis Biosimilar Revenue by Application (2021-2026) & (US$ Million) Table 120. Europe Psoriasis Biosimilar Revenue by Application (2027-2032) & (US$ Million) Table 121. Europe Psoriasis Biosimilar Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Europe Psoriasis Biosimilar Revenue by Country (2021-2026) & (US$ Million) Table 123. Europe Psoriasis Biosimilar Revenue by Country (US$ Million) & (2027-2032) Table 124. China Psoriasis Biosimilar Revenue by Type (2021-2026) & (US$ Million) Table 125. China Psoriasis Biosimilar Revenue by Type (2027-2032) & (US$ Million) Table 126. China Psoriasis Biosimilar Revenue by Application (2021-2026) & (US$ Million) Table 127. China Psoriasis Biosimilar Revenue by Application (2027-2032) & (US$ Million) Table 128. Asia Psoriasis Biosimilar Revenue by Type (2021-2026) & (US$ Million) Table 129. Asia Psoriasis Biosimilar Revenue by Type (2027-2032) & (US$ Million) Table 130. Asia Psoriasis Biosimilar Revenue by Application (2021-2026) & (US$ Million) Table 131. Asia Psoriasis Biosimilar Revenue by Application (2027-2032) & (US$ Million) Table 132. Asia Psoriasis Biosimilar Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Asia Psoriasis Biosimilar Revenue by Region (US$ Million) & (2021-2026) Table 134. Asia Psoriasis Biosimilar Revenue by Region (US$ Million) & (2027-2032) Table 135. SAMEA Psoriasis Biosimilar Revenue by Type (2021-2026) & (US$ Million) Table 136. SAMEA Psoriasis Biosimilar Revenue by Type (2027-2032) & (US$ Million) Table 137. SAMEA Psoriasis Biosimilar Revenue by Application (2021-2026) & (US$ Million) Table 138. SAMEA Psoriasis Biosimilar Revenue by Application (2027-2032) & (US$ Million) Table 139. SAMEA Psoriasis Biosimilar Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. SAMEA Psoriasis Biosimilar Revenue by Country (2021-2026) & (US$ Million) Table 141. SAMEA Psoriasis Biosimilar Revenue by Country (US$ Million) & (2027-2032) Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Psoriasis Biosimilar Image Figure 2. Global Psoriasis Biosimilar Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Psoriasis Biosimilar Market Size Share 2021 VS 2025 VS 2032 Figure 4. TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab) Image Figure 5. Other Biosimilars Image Figure 6. Global Psoriasis Biosimilar Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Psoriasis Biosimilar Market Size Share 2021 VS 2025 VS 2032 Figure 8. Plaque Psoriasis Image Figure 9. Psoriatic Arthritis Image Figure 10. Other Image Figure 11. Global Psoriasis Biosimilar Market Size (US$ Million) & (2021-2032) Figure 12. Global Psoriasis Biosimilar Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Psoriasis Biosimilar Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Psoriasis Biosimilar Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Psoriasis Biosimilar Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Psoriasis Biosimilar Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Psoriasis Biosimilar Revenue Market Share by Type (2021-2032) Figure 19. Global Psoriasis Biosimilar Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Psoriasis Biosimilar Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Psoriasis Biosimilar Revenue Market Share by Application (2021-2032) Figure 22. North America Psoriasis Biosimilar Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Psoriasis Biosimilar Revenue Share by Type (2021-2032) Figure 24. North America Psoriasis Biosimilar Revenue Share by Application (2021-2032) Figure 25. North America Psoriasis Biosimilar Revenue Share by Country (2021-2032) Figure 26. United States Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Psoriasis Biosimilar Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Psoriasis Biosimilar Revenue Share by Type (2021-2032) Figure 31. Europe Psoriasis Biosimilar Revenue Share by Application (2021-2032) Figure 32. Europe Psoriasis Biosimilar Revenue Share by Country (2021-2032) Figure 33. Germany Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Psoriasis Biosimilar Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Psoriasis Biosimilar Revenue Share by Type (2021-2032) Figure 43. China Psoriasis Biosimilar Revenue Share by Application (2021-2032) Figure 44. Asia Psoriasis Biosimilar Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Psoriasis Biosimilar Revenue Share by Type (2021-2032) Figure 46. Asia Psoriasis Biosimilar Revenue Share by Application (2021-2032) Figure 47. Asia Psoriasis Biosimilar Revenue Share by Region (2021-2032) Figure 48. Japan Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Psoriasis Biosimilar Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Psoriasis Biosimilar Revenue Share by Type (2021-2032) Figure 56. SAMEA Psoriasis Biosimilar Revenue Share by Application (2021-2032) Figure 57. SAMEA Psoriasis Biosimilar Revenue Share by Country (2021-2032) Figure 58. Brazil Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Psoriasis Biosimilar Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
  • Other Biosimilars
Applications
  • Plaque Psoriasis
  • Psoriatic Arthritis
  • Other
Companies covered
  • Amgen Inc
  • Celltrion
  • Coherus BioSciences
  • Fresenius Kabi
  • GenScript
  • Gyros Protein Technologies AB
  • Hoffmann-La Roche Ltd
  • Novartis International AG
  • Reddy's Laboratories
  • Samsung Bioepis
  • Samsung Bioepis Co., Ltd.
  • Viatris
  • Pfizer Inc.
  • Merck KGaA
  • Sandoz

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Psoriasis Biosimilar Market by Type
  3. 1.2.1 Global Psoriasis Biosimilar Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 TNF-Alpha Inhibitors (Infliximab, Etanercept, Adalimumab)
  5. 1.2.3 Other Biosimilars
  6. 1.3 Psoriasis Biosimilar Market by Application
  7. 1.3.1 Global Psoriasis Biosimilar Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Plaque Psoriasis
  9. 1.3.3 Psoriatic Arthritis
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Psoriasis Biosimilar Market Dynamics
  1. 2.1 Psoriasis Biosimilar Industry Trends
  2. 2.2 Psoriasis Biosimilar Industry Drivers
  3. 2.3 Psoriasis Biosimilar Industry Opportunities and Challenges
  4. 2.4 Psoriasis Biosimilar Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Psoriasis Biosimilar Market Perspective (2021-2032)
  2. 3.2 Global Psoriasis Biosimilar Growth Trends by Region
  3. 3.2.1 Global Psoriasis Biosimilar Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Psoriasis Biosimilar Market Size by Region (2021-2026)
  5. 3.2.3 Global Psoriasis Biosimilar Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Psoriasis Biosimilar Revenue by Players
  2. 4.1.1 Global Psoriasis Biosimilar Revenue by Players (2021-2026)
  3. 4.1.2 Global Psoriasis Biosimilar Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Psoriasis Biosimilar Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Psoriasis Biosimilar Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Psoriasis Biosimilar Key Players Headquarters & Area Served
  7. 4.4 Global Psoriasis Biosimilar Players, Product Type & Application
  8. 4.5 Global Psoriasis Biosimilar Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Psoriasis Biosimilar Market CR5 and HHI
  11. 4.6.3 2025 Psoriasis Biosimilar Tier 1, Tier 2, and Tier 3
5 Psoriasis Biosimilar Market Size by Type
  1. 5.1 Global Psoriasis Biosimilar Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Psoriasis Biosimilar Revenue by Type (2021-2032)
  3. 5.3 Global Psoriasis Biosimilar Revenue Market Share by Type (2021-2032)
6 Psoriasis Biosimilar Market Size by Application
  1. 6.1 Global Psoriasis Biosimilar Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Psoriasis Biosimilar Revenue by Application (2021-2032)
  3. 6.3 Global Psoriasis Biosimilar Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Amgen Inc
  2. 7.1.1 Amgen Inc Company Information
  3. 7.1.2 Amgen Inc Business Overview
  4. 7.1.3 Amgen Inc Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Amgen Inc Psoriasis Biosimilar Product Portfolio
  6. 7.1.5 Amgen Inc Recent Developments
  7. 7.2 Celltrion
  8. 7.2.1 Celltrion Company Information
  9. 7.2.2 Celltrion Business Overview
  10. 7.2.3 Celltrion Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Celltrion Psoriasis Biosimilar Product Portfolio
  12. 7.2.5 Celltrion Recent Developments
  13. 7.3 Coherus BioSciences
  14. 7.3.1 Coherus BioSciences Company Information
  15. 7.3.2 Coherus BioSciences Business Overview
  16. 7.3.3 Coherus BioSciences Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Coherus BioSciences Psoriasis Biosimilar Product Portfolio
  18. 7.3.5 Coherus BioSciences Recent Developments
  19. 7.4 Fresenius Kabi
  20. 7.4.1 Fresenius Kabi Company Information
  21. 7.4.2 Fresenius Kabi Business Overview
  22. 7.4.3 Fresenius Kabi Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Fresenius Kabi Psoriasis Biosimilar Product Portfolio
  24. 7.4.5 Fresenius Kabi Recent Developments
  25. 7.5 GenScript
  26. 7.5.1 GenScript Company Information
  27. 7.5.2 GenScript Business Overview
  28. 7.5.3 GenScript Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  29. 7.5.4 GenScript Psoriasis Biosimilar Product Portfolio
  30. 7.5.5 GenScript Recent Developments
  31. 7.6 Gyros Protein Technologies AB
  32. 7.6.1 Gyros Protein Technologies AB Company Information
  33. 7.6.2 Gyros Protein Technologies AB Business Overview
  34. 7.6.3 Gyros Protein Technologies AB Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Gyros Protein Technologies AB Psoriasis Biosimilar Product Portfolio
  36. 7.6.5 Gyros Protein Technologies AB Recent Developments
  37. 7.7 Hoffmann-La Roche Ltd
  38. 7.7.1 Hoffmann-La Roche Ltd Company Information
  39. 7.7.2 Hoffmann-La Roche Ltd Business Overview
  40. 7.7.3 Hoffmann-La Roche Ltd Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Hoffmann-La Roche Ltd Psoriasis Biosimilar Product Portfolio
  42. 7.7.5 Hoffmann-La Roche Ltd Recent Developments
  43. 7.8 Novartis International AG
  44. 7.8.1 Novartis International AG Company Information
  45. 7.8.2 Novartis International AG Business Overview
  46. 7.8.3 Novartis International AG Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Novartis International AG Psoriasis Biosimilar Product Portfolio
  48. 7.8.5 Novartis International AG Recent Developments
  49. 7.9 Reddy's Laboratories
  50. 7.9.1 Reddy's Laboratories Company Information
  51. 7.9.2 Reddy's Laboratories Business Overview
  52. 7.9.3 Reddy's Laboratories Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Reddy's Laboratories Psoriasis Biosimilar Product Portfolio
  54. 7.9.5 Reddy's Laboratories Recent Developments
  55. 7.10 Samsung Bioepis
  56. 7.10.1 Samsung Bioepis Company Information
  57. 7.10.2 Samsung Bioepis Business Overview
  58. 7.10.3 Samsung Bioepis Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Samsung Bioepis Psoriasis Biosimilar Product Portfolio
  60. 7.10.5 Samsung Bioepis Recent Developments
  61. 7.11 Samsung Bioepis Co., Ltd.
  62. 7.11.1 Samsung Bioepis Co., Ltd. Company Information
  63. 7.11.2 Samsung Bioepis Co., Ltd. Business Overview
  64. 7.11.3 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Samsung Bioepis Co., Ltd. Psoriasis Biosimilar Product Portfolio
  66. 7.11.5 Samsung Bioepis Co., Ltd. Recent Developments
  67. 7.12 Viatris
  68. 7.12.1 Viatris Company Information
  69. 7.12.2 Viatris Business Overview
  70. 7.12.3 Viatris Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Viatris Psoriasis Biosimilar Product Portfolio
  72. 7.12.5 Viatris Recent Developments
  73. 7.13 Pfizer Inc.
  74. 7.13.1 Pfizer Inc. Company Information
  75. 7.13.2 Pfizer Inc. Business Overview
  76. 7.13.3 Pfizer Inc. Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Pfizer Inc. Psoriasis Biosimilar Product Portfolio
  78. 7.13.5 Pfizer Inc. Recent Developments
  79. 7.14 Merck KGaA
  80. 7.14.1 Merck KGaA Company Information
  81. 7.14.2 Merck KGaA Business Overview
  82. 7.14.3 Merck KGaA Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Merck KGaA Psoriasis Biosimilar Product Portfolio
  84. 7.14.5 Merck KGaA Recent Developments
  85. 7.15 Sandoz
  86. 7.15.1 Sandoz Company Information
  87. 7.15.2 Sandoz Business Overview
  88. 7.15.3 Sandoz Psoriasis Biosimilar Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Sandoz Psoriasis Biosimilar Product Portfolio
  90. 7.15.5 Sandoz Recent Developments
8 North America
  1. 8.1 North America Psoriasis Biosimilar Revenue (2021-2032)
  2. 8.2 North America Psoriasis Biosimilar Revenue by Type (2021-2032)
  3. 8.2.1 North America Psoriasis Biosimilar Revenue by Type (2021-2026)
  4. 8.2.2 North America Psoriasis Biosimilar Revenue by Type (2027-2032)
  5. 8.3 North America Psoriasis Biosimilar Revenue Share by Type (2021-2032)
  6. 8.4 North America Psoriasis Biosimilar Revenue by Application (2021-2032)
  7. 8.4.1 North America Psoriasis Biosimilar Revenue by Application (2021-2026)
  8. 8.4.2 North America Psoriasis Biosimilar Revenue by Application (2027-2032)
  9. 8.5 North America Psoriasis Biosimilar Revenue Share by Application (2021-2032)
  10. 8.6 North America Psoriasis Biosimilar Revenue by Country
  11. 8.6.1 North America Psoriasis Biosimilar Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Psoriasis Biosimilar Revenue by Country (2021-2026)
  13. 8.6.3 North America Psoriasis Biosimilar Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Psoriasis Biosimilar Revenue (2021-2032)
  2. 9.2 Europe Psoriasis Biosimilar Revenue by Type (2021-2032)
  3. 9.2.1 Europe Psoriasis Biosimilar Revenue by Type (2021-2026)
  4. 9.2.2 Europe Psoriasis Biosimilar Revenue by Type (2027-2032)
  5. 9.3 Europe Psoriasis Biosimilar Revenue Share by Type (2021-2032)
  6. 9.4 Europe Psoriasis Biosimilar Revenue by Application (2021-2032)
  7. 9.4.1 Europe Psoriasis Biosimilar Revenue by Application (2021-2026)
  8. 9.4.2 Europe Psoriasis Biosimilar Revenue by Application (2027-2032)
  9. 9.5 Europe Psoriasis Biosimilar Revenue Share by Application (2021-2032)
  10. 9.6 Europe Psoriasis Biosimilar Revenue by Country
  11. 9.6.1 Europe Psoriasis Biosimilar Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Psoriasis Biosimilar Revenue by Country (2021-2026)
  13. 9.6.3 Europe Psoriasis Biosimilar Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Psoriasis Biosimilar Revenue (2021-2032)
  2. 10.2 China Psoriasis Biosimilar Revenue by Type (2021-2032)
  3. 10.2.1 China Psoriasis Biosimilar Revenue by Type (2021-2026)
  4. 10.2.2 China Psoriasis Biosimilar Revenue by Type (2027-2032)
  5. 10.3 China Psoriasis Biosimilar Revenue Share by Type (2021-2032)
  6. 10.4 China Psoriasis Biosimilar Revenue by Application (2021-2032)
  7. 10.4.1 China Psoriasis Biosimilar Revenue by Application (2021-2026)
  8. 10.4.2 China Psoriasis Biosimilar Revenue by Application (2027-2032)
  9. 10.5 China Psoriasis Biosimilar Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Psoriasis Biosimilar Revenue (2021-2032)
  2. 11.2 Asia Psoriasis Biosimilar Revenue by Type (2021-2032)
  3. 11.2.1 Asia Psoriasis Biosimilar Revenue by Type (2021-2026)
  4. 11.2.2 Asia Psoriasis Biosimilar Revenue by Type (2027-2032)
  5. 11.3 Asia Psoriasis Biosimilar Revenue Share by Type (2021-2032)
  6. 11.4 Asia Psoriasis Biosimilar Revenue by Application (2021-2032)
  7. 11.4.1 Asia Psoriasis Biosimilar Revenue by Application (2021-2026)
  8. 11.4.2 Asia Psoriasis Biosimilar Revenue by Application (2027-2032)
  9. 11.5 Asia Psoriasis Biosimilar Revenue Share by Application (2021-2032)
  10. 11.6 Asia Psoriasis Biosimilar Revenue by Country
  11. 11.6.1 Asia Psoriasis Biosimilar Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Psoriasis Biosimilar Revenue by Country (2021-2026)
  13. 11.6.3 Asia Psoriasis Biosimilar Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Psoriasis Biosimilar Revenue (2021-2032)
  2. 12.2 SAMEA Psoriasis Biosimilar Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Psoriasis Biosimilar Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Psoriasis Biosimilar Revenue by Type (2027-2032)
  5. 12.3 SAMEA Psoriasis Biosimilar Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Psoriasis Biosimilar Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Psoriasis Biosimilar Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Psoriasis Biosimilar Revenue by Application (2027-2032)
  9. 12.5 SAMEA Psoriasis Biosimilar Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Psoriasis Biosimilar Revenue by Country
  11. 12.6.1 SAMEA Psoriasis Biosimilar Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Psoriasis Biosimilar Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Psoriasis Biosimilar Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst